Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts

Blood, Vol. 107, Issue 1, 63-72, January 1, 2006
This Article
Right arrow Abstract
Right arrow Full Text
Services
Right arrow Email this article to a friend
Right arrow Alert me to new issues of the journal
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef

Long-term immune reconstitution in RAG-1-deficient mice treated by retroviral gene therapy: a balance between efficiency and toxicity
Blood Lagresle-Peyrou et al. 107: 63

Supplemental materials for: Lagresle-Peyrou et al

Files in this Data Supplement:

  • Figure S1 (PDF, 37.1 KB) - A. Schematic representation of retroviral vector. The location of the probes and primers has been noticed. B. Southern blot analysis of genomic DNA from various organs. Mouse A had developped the lymphoproliferative syndrome. Mouse B presented a total immune reconstitution. BM= bone-marrow. 10 µg of genomic DNA was digested with KpnI enzyme and Southern blot was performed according to standard protocols. DNA was hybridized with a [-32P dCTP] probe located in the cDNA of human RAG-1. The resulting hybridizing bands were visualized using a Molecular Dynamic Storm 860 Phosphoimager and its accompanying software. C. Northern blot analysis on the packaging cells. RNA was isolated from the non transfected and hRAG-1 transfected packaging cells and 5 µg was electrophoresed in formaldehyde agarose gel. The membrane was hybridized with the same probe as used for the Southern blot analysis. The resulting hybridizing bands were visualized and quantified using a Molecular Dynamic Storm 860 Phosphoimager and its accompanying software. RNA loading was evaluated after Ethidium bromide staining of the gel.

  • Figure S2. Murine RAG-2 (mRAG-2) expression was determinated on the RNA extracted from thymus, spleen or bone marrow of a wild-type C57BL/10 mouse and the leukemic mouse (PDF, 11.2 KB) - mRAG-2 expression was measured following the protocol described in materials and methods for the quantification of hRAG-1. To account for variations due to RNA extraction and the RT reaction, the measured level of mRAG-2 transgene mRNA was normalized against an endogenous RNA control, PO mRNA, an acidic ribosomal phosphoprotein ubiquitly expressed in all murine cells. Ratios were calculated by comparing the mRAG-2 mRNA expression levels (mRAG-2/PO) in the tested samples with murine RAG-2 expression levels in the thymus of wild type C57BL/10 mice (mRAG-2/PO). The mRAG-2 transcript expression value was calculated as a percentage of the reference mRAG-1/PO ratio in the thymus.
    % mRAG-2 expression = (mRAG-2/PO) in the tested sample/(mRAG-2/PO) in WT mouse × 100
    ND: not done in the organ specified.




This Article
Right arrow Abstract
Right arrow Full Text
Services
Right arrow Email this article to a friend
Right arrow Alert me to new issues of the journal
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020